Background-Klotho is known to function as a cofactor for the phosphatonin, fibroblast growth factor (FGF)-23 at the kidney.
transmembrane protein, expresses at high levels in renal distal tubular epithelial cells and, to a lesser extent, in the parathyroid gland, placenta, prostate, and small intestine. 1 Cleavage of the extracellular domain of Klotho generates a secreted, soluble form of the protein found in blood, urine, and cerebrospinal fluid. 2 Klotho knockout mice (Klotho Ϫ/Ϫ ) develop a syndrome resembling patients with chronic kidney disease (CKD), shortened lifespan, hyperphosphatemia, and multiple accelerated agerelated disorders, including extensive, diffuse artery calcification (VC). 3 
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Studies have demonstrated that Klotho comprises antiaging and cardiovasculoprotective properties: Klotho resists oxidative stress by the inhibition of insulin and insulin-like growth factor-1 (IGF-1) signaling pathways. 4 Klotho has also been shown to improve endothelium-dependent vasodilatation through increasing nitric oxide production. 5, 6 In addition, Moe and colleagues 7 recently showed that transgenic Klotho overexpressing mice with CKD develop significantly less calcification in comparison with wild-type mice. Soluble Klotho was responsible for direct inhibition of mineralization, phosphate uptake, and dedifferentiation of cells of the vascular wall.
Accelerated vascular dysfunction and resultant calcification is highly prevalent in patients with CKD, diabetes, and premature aging and is a major contributor to premature cardiovascular death in these patients. 8, 9 It is currently unknown whether Klotho is expressed endogenously in the artery wall and whether it may impart similar vasculoprotective functions to its soluble, kidney-derived counterpart.
It is believed that Klotho expression in specific tissues renders them responsive to the circulating phosphatonin, fibroblast growth factor 23 (FGF-23). Klotho functions as a cofactor for FGF-23 in kidney by converting fibroblast growth factor receptor 1 (FGFR-1) into a specific receptor for FGF-23. Studies have shown that formation of a Klotho/ FGFR-1 receptor complex may be the principal effector site for FGF-23 phosphaturic effects in kidney. 1, 10 Because FGF-23 levels begin to rise in the early stages of CKD, Klotho/FGFR-1/FGF-23 signaling in kidney is an important mechanism that functions to counteract hyperphosphatemia and resulting vascular complications. However, both clinical and basic studies have demonstrated conflicting evidence as to whether FGF-23 imparts a protective or a harmful role on vasculature under stress. [11] [12] [13] [14] [15] Recent studies have implicated reduced Klotho tissue levels as a cause of FGF-23 resistance at the parathyroid gland in CKD rats. 16, 17 Whether vascular resistance to FGF-23 occurs in CKD that could mask its effects on the vasculature is an important question that needs addressing.
Vitamin D deficiency is a prevalent condition in CKD patients, and vitamin D receptor (VDR) activators are routinely used to prevent secondary hyperparathyroidism. Emerging evidence has implicated rising FGF-23 levels in CKD as the cause of declining active 1,25dihydroxyvitamin D (1,25(OH) 2 D; calcitriol) levels in kidney. 15 Clinical studies have demonstrated that serum calcitriol levels are inversely correlated with coronary artery calcification in the general population. 18, 19 These studies therefore suggest that vitamin D may be playing an anticalcific role on arteries.
In this study, we describe for the first time endogenous Klotho expression in human artery. We present data for vascular-produced Klotho as an endogenous inhibitor of calcification and as a cofactor for FGF-23 signaling. In addition, we provide evidence for the reversal of CKDmediated, Klotho-dependent vascular resistance to FGF-23 after vascular VDR activation.
Methods

Human Samples
Human samples were collected from healthy people donating a kidney and CKD patients undergoing a renal transplant. Human artery collection was performed at the University Hospital Coventry and Warwickshire NHS Trust, United Kingdom. Ethical approval was obtained from the Coventry Research Ethics Committee (05/ Q2802/26), United Kingdom.
Arterial Explants Organ Culture
Epigastric and renal arteries from patients with CKD and from healthy kidney donors) were dissected, and arterial rings were placed in DMEM (Invitrogen, Carlsbad, CA). Arteries were then treated with 100 nmol calcitriol or 300 nmol paricalcitol for 48 hours before harvesting for analysis.
Cell Culture
Commercially available human aortic smooth muscle cells (HA-SMCs) were obtained from 3 different age-matched sources (lot 0295, 0573, 3523; ScienCell Research Laboratory, Carlsbad, CA). All in vitro experiments using HA-SMCs were repeated using all 3 cell sources. The n number corresponds to the number of total repeat experiments performed collectively by using all 3 cell sources. HA-SMCs were cultured in 5% CO 2 /37°C incubator and grown with smooth muscle cell medium containing 0.5 mmol/L phosphate and 1.6 mmol/L calcium (catalog No. 1101; ScienCell Research Laboratory, Carlsbad, CA) for seeding.
Treatment of cells were performed using DMEM (catalog No. 1013, Invitrogen, Carlsbad, CA). Addition of 0.5% fetal bovine serum to DMEM was used as starvation medium for short-term experiments to assess the role of Ca, P i , and tumor necrosis factor ␣ (TNF-␣). Charcoal-stripped serum ( 
Antibodies for Western Blot and Immunoprecipitation
All antibodies were prepared in Tris-buffered saline with 0.2% Tween-20 for Western blot, concentration of antibodies used in this study: Klotho (catalog No. Ab75023; Abcam, Cambridge, MA) 1:500; Runt-related transcription factor 2 (Runx2) ( 
Calcification
Calcification was visualized at 21 days after treatment by Alizarin red staining as previously described. 20 Calcification was also quantified by using the Arsenazo III (Fisher Scientific, Pittsburgh, PA) method. Please refer to the in online-only Data Supplement Methods for detailed descriptions.
Statistical Analysis
All experiments were performed at least 3 times, and the results were expressed as the meanϮstandard error. Analysis was performed by using descriptive statistics, 2-tailed paired t test or 1-way ANOVA followed by Bonferonni post hoc analysis as stated in the representative figure legends (Figures 1 through 6) . Probability values Ͻ0.05 were considered as statistically significant.
Supplementary Methods
Detailed description for immunohistochemistry, immunocytochemistry, immunoprecipitation, Western blotting, and polymerase chain reaction protocols used is provided in the online-only Data Supplement Methods.
Results
CKD Is a State of Vascular Klotho, FGFR-1, and FGFR-3 Deficiency
We show, for the first time, Klotho protein expression in human arteries ( Figure 1A) and have investigated the expression profile of Klotho in human arteries from healthy individuals and patients with CKD. Immunohistochemistry analysis demonstrated Klotho protein expression in the medial layer of arteries from healthy individuals, but marked reduction in arteries from patients with CKD. Artery Klotho protein quantification with Western blot confirmed this observation ( Figure 1B ; demographic patient data in online-only Data Supplement Table I ). Reduced vascular Klotho protein expression in CKD patients was associated with extensive medial calcification assessed by Alizarin red staining. We found that 0 of 10 (0%) of arteries from healthy individuals and 6 of 10 (60%) of CKD arteries showed calcification (data not shown). In addition, we have shown that arteries from CKD patients exhibited increased levels of Runx2, suggesting osteogenic transformation of vascular cells in comparison with healthy controls (PϽ0.01) ( Figure 1B ). Our results suggest that Klotho may be involved in the vascular dysfunction of CKD. Concomitant FGFR-1 and FGFR-3 protein expression mirrored Klotho expression in human arteries ( Figure 1A ).
The Uremic Environment Suppresses Endogenous HA-SMC Klotho, FGFR-1, and FGFR-3 Expression Associated With Osteo/Chondrocytic Transformation in Vitro
To determine whether uremia suppressed endogenous Klotho expression, we used pooled serum from healthy individuals and patients with CKD (biochemical analysis in online-only Data Supplement Table II ). HA-SMCs cultured with 10% uremic serum showed a significant decline in Klotho, FGFR-1, and FGFR-3 expression at 72 hours in comparison with the healthy treatment group ( Figure 1C ). Note that we did not find FGFR-2 and -4 expression in HA-SMCs (data not shown).
Hyperphosphatemic or hypercalcemic conditions have been shown to induce osteogenic transformation of vascular smooth muscle cells (VSMCs), an important process that orchestrates the development of calcification. 21, 22 We therefore evaluated whether hyperphosphatemia and/or hypercalcemia downregulate Klotho, FGFR-1, or FGFR-3 expression. HA-SMCs were treated with calcium, phosphate, or calcium and phosphate at concentrations arteries from patients with CKD are exposed to. Klotho, FGFR-1, and FGFR-3 expression was significantly reduced after treatment with calcium concentrations of 2.7 mmol/L or 5.0 mmol/L at 12 hours and remained reduced at 24 hours ( Figure 2A ). Combined treatment with increased calcium and phosphate concentrations had similar suppressive effects ( Figure 2C ). Treatment with phosphate concentrations of 2.0 mmol/L or 5.0 mmol/L suppressed Klotho expression only at 24 hours, whereas FGFR-1 and FGFR-3 suppression was already observed at 12 hours ( Figure 2B ). Accumulating evidence suggests that inflammatory stress such as TNF-␣ seen in CKD and diabetes mellitus is an important risk factor for VC. 23 Therefore, to determine whether proinflammatory stress may itself downregulate Klotho, FGFR-1, or FGFR-3, HA-SMCs were treated with TNF-␣. All 3 proteins were suppressed gradually after 12 hours of TNF-␣ treatment at 20 ng/mL, with further suppression over 36 hours ( Figure 2D ). In parallel with Klotho, FGFR-1, and FGFR-3 suppression, Runt-related transcription factor 2 (Runx2) was upregulated, indicating HA-SMC transformation to the calcifying phenotype ( 
Klotho Deficiency Potentiates the Development of HA-SMC Calcification
To determine the roles of local HA-SMC-expressed Klotho in vascular dysfunction, we investigated whether endogenous HA-SMC Klotho deficiency is involved in the development of accelerated VC. We first generated a HA-SMC Klotho knockdown model by using Klotho siRNA (online-only Data Supplement Figures I and II). To determine the role of Klotho deficiency in the development of calcification, HA-SMCs were retransfected with Klotho siRNA every other day. We have validated our Klotho siRNA transfection efficiency over long-term 21-day cultures stressed with calcification medium (online-only Data Supplement Figure III) .
Klotho siRNA transfected and control cells were cultured with high calcium and phosphate concentrations for 21 days. The Klotho siRNA-transfected group exhibited significant accelerated calcification in comparison with the empty vector and nontransfected groups ( Figure 3A) . Klotho, FGFR-1, and FGFR-3 protein expression were already suppressed in HA-SMCs cultured under calcifying stress and declined further with its cognate siRNA construct with the consequence of further extracellular calcium deposition ( Figure 3B ). and patients with CKD (nϭ11) demonstrated significantly lower, almost undetectable protein levels in arteries from CKD patients. Arteries from CKD patients also showed increased Runx2 expression, suggesting osteogenic transformation (PϽ0.01) (demographic patient data are provided in online-only Data Supplement Table I) . C, Klotho, FGFR-1, and FGFR-3 protein are expressed in human aortic smooth muscle cells (HA-SMCs). When HA-SMCs were exposed to 10% pooled uremic serum from patients with CKD, expression of Klotho, FGFR-1, and FGFR-3 protein decreased significantly at 72 hours, compared with the treatment group exposed to 10% pooled serum from healthy individuals (PϽ0.05, nϭ6) (composition of serum used for treatment is described in online-only Data Supplement  Table II ). One-way ANOVA followed by Bonferroni post hoc analysis was for analysis in B and C. FGFR indicates fibroblast growth factor receptor. Mechanistic studies confirmed HA-SMC change to a calcifying phenotype. Key cellular regulatory proteins mirrored this transformation with upregulation of Runx2, indicating osteogenic transformation and suppression of myocardin and SRF ( Figure 3C ). Myocardin and the associated SRF are key regulators to maintain HA-SMC in a contractile, SMC phenotype. 24 This regulation is particularly important in the pathogenesis of calcification, because SMCs convert from a contractile to a secretory phenotype after artery injury. 25 This is paralleled with increased Runx2 expression, the master regulator toward a calcifying osteogenic phenotype. Increased alkaline phosphatase activity, a key bone-forming enzyme, in the supernatant of cells exposed to calcifying stress further mirrors these intracellular signal changes ( Figure 3D ). Our results, using Klotho siRNA pretreatment accelerates HA-SMC transformation to a calcifying phenotype, confirm the importance of SMC.
Loss of Smooth Muscle Cell Contractile Phenotype is an Early Event in Klotho Deficiency
We next sought to further characterize the role of Klotho in regulating the smooth muscle cell contractile phenotype. HA-SMCs were cultured in high calcium and high phosphate for 48 hours. Klotho and the upstream smooth muscle cell markers smoothelin ␣-SMA and calponin were suppressed. Klotho knockdown with Klotho siRNA in HA-SMCs treated with calcifying stress further suppressed calponin expression. Smoothelin and probably ␣-SMA were already suppressed maximally with high calcium and high phosphate, and no further suppression could be achieved after Klotho knockdown ( Figure 3E ). It is noteworthy that Runx2 expression was elevated in the nontransfected and empty vector groups with further elevation in the Klotho knockdown group confirming our observations in our long-term 21-day model.
Reduced HA-SMC Klotho, FGFR-1, and FGFR-3 Expression and Their Physical Dissociation Under Calcifying Stress Mediates Resistance to FGF-23
Immunocytochemistry analysis revealed coexpression of Klotho with FGFR-1 and FGFR-3 in HA-SMCs with a markedly reduced expression under extracellular high calcium and phosphate stress at 6 hours ( Figure 4A ). Coimmunoprecipitation studies revealed physical association between Klotho-FGFR-1 and Klotho-FGFR-3 ( Figure 4B ). Physical association ratio, calculated by optical density of target protein/immunoprecipitated protein, revealed significant dissociation of Klotho-FGFR-1 and Klotho-FGFR-3 in HA-SMCs under high calcium stress. These results suggest that there is a concomitant decline of Klotho, FGFR-1, and FGFR-3 expression and physical dissociation contributing to progression of VSMC dysfunction.
Previous studies have shown that FGF-23 upregulates p-ERK and p-AKT signaling pathways in renal proximal tubule epithelial cells. 26 We report that HA-SMCs treated with FGF-23 at 5 ng/mL for 12 hours upregulated p-ERK and p-AKT; however, Klotho siRNA mitigated these effects, rendering VSMCs FGF-23 resistant ( Figure 4C ). p-ERK and p-AKT have been previously associated with mitogenic and cell survival pathways, our results showed that HA-SMCs cultured in 10% serum from healthy individuals after adding FGF-23 5 ng/mL significantly stimulated proliferation of HA-SMCs. Klotho knockdown by Klotho siRNA transfection for 24 hours before addition of 10% serum from healthy individuals, however, mitigated these effects ( Figure 4D ). Furthermore, HA-SMCs cultured in 10% uremic serum containing high FGF-23 concentrations from CKD patients significantly stimulated cell proliferation, and these effects were also reduced by Klotho knockdown (Figure 4E ). Klotho-FGF-23 signaling may play a pivotal role in increased cell proliferation. These results suggest that endogenous Klotho renders VSMCs a target for FGF-23 signaling and that Klotho deficiency may mediate vascular resistance in CKD.
Restoration of Klotho by VDR Activation Confers HA-SMCs FGF-23 Responsive and Unmasks FGF-23 Calcification Inhibitory Effects
We show that HA-SMCs pretreatment with active calcitriol could restore Klotho expression in procalcific environments and with the response at much higher concentrations with inactive 25-hydroxyvitamin D (25(OH)D; calcidiol), postulating local activation. Calcitriol restored FGFR-1 expression, but little effect was found with calcidiol at 24 hours. FGFR-3 expression was restored only by 50 nmol/L calcitriol treatment ( Figure 5A ).
In addition, HA-SMCs treated with calcification medium (CM), FGF-23, or calcitriol alone stimulated cell proliferation, with FGF-23 being the most potent stimulator. Treatment with FGF-23 together with CM did not increase cell proliferation in comparison with CM treatment alone. This suggests cellular Klotho deficiency under procalcific stress, resulting in FGF-23 resistance. However, combination treatment of FGF-23 and CM following pretreatment with calcitriol caused significant stimulation of cell proliferation. This proliferative effect was mitigated after Klotho siRNA pretreatment ( Figure 5B ). Furthermore, we demonstrate for the first time that FGF-23 was able to significantly inhibit extracellular calcium deposition following restoration of Klotho after pretreatment with calcitriol These beneficial effects were again reversed after suppressing Klotho protein synthesis with Klotho siRNA ( Figure 5C ). This confirms the importance of vascular VDR activation to reverse stressinduced suppression of vascular Klotho to restore FGF-23 responsiveness. Figure 2 (Continued) . treatment. Runx2 protein expression was detectable at 12 hours, with increasing expression over the following treatment period. Target protein compared with its control: nϭ6. One-way ANOVA was used to compare a target protein among treatment groups within a time point. Probability values from 1-way ANOVA are Ͻ0.001 in A through D. Bonferonni post hoc analysis was then performed, and the probability values are provided in the figure. FGFR indicates fibroblast growth factor receptor; TNF, tumor necrosis factor; HA-SMC, human aortic smooth muscle cells.
Organ cultures of human arteries from patients with CKD exhibited significant upregulation of Klotho mRNA levels following 48 hours of calcitriol or paricalcitol (a synthetic VDR activator) treatment. This treatment effect was not observed in arteries from healthy individuals ( Figure 6 ). FGFR-1 responded in parallel, with restoration of mRNA expression in arteries exposed to uremia after treatment with VDR activators calcitriol or paricalcitol to levels observed in arteries from healthy individuals. FGFR-3 mRNA levels in arteries from patients with CKD remained suppressed even after VDR activator treatment. Basal Klotho RNA level in arteries was quantified immediately after removal from the patient. The same levels of Klotho RNA were expressed as already described after 48 hours, as shown in Figure 6 .
Discussion
We show that high Klotho expression in human arteries from healthy individuals and from patients with CKD are severely Klotho protein deficient. We provide evidence for functional Klotho protein expression in human VSMCs. Published data show no Klotho expression in animal (mouse or rat) vasculature, which was confirmed in our laboratory. Further in vitro studies using HA-SMCs demonstrated that chronic stress factors including proinflammatory TNF-␣, disordered mineral levels, and uremia drives Klotho deficiency. These results may explain in part the relationship between inflammation and diseases characterized by accelerated aging of organs, including CKD. A recent study has shown that inflammatory cytokines, such as TNF-␣ and TNF-like weak inducer of apoptosis, downregulate Klotho expression through an nuclear factor B-dependent mechanism in kidney. 27 A similar pathway could contribute to suppression of Klotho in vascular cells and unmask arteries to chronic metabolic and inflammatory stress, resulting in vascular calcification. Further studies are needed to determine whether such inflammatory cytokines in circulation or produced locally are the main drivers of Klotho suppression.
Previous studies have shown that osteogenic transformation of VMSCs renders them mineralization competent to secrete an osteoid-like extracellular matrix that calcifies over a defined time course. 22 Our results show that suppression of Klotho was associated with upregulation of Runx2, with VSMC phenotype transformation. Previous studies have also shown that uremic and similar metabolic stressors can suppress Klotho at the parathyroid gland. 17, 28 Our results support these findings and provide the first evidence that CKD is a state of local, vascular Klotho deficiency.
Upregulation of Runx2 orchestrates osteoblastic differentiation of VSMCs by regulating downstream bone-related proteins, including alkaline phosphatase and osteocalcin. The process of VSMCs dedifferentiation from a contractile to a secretory phenotype is co-ordinated by Myocardin, which functions as a cofactor for the transcription factor, SRF that binds to CArG-box motif, to regulate transcription of smooth muscle contractile genes, including ␣-SMA. 24, 29, 30 Our data suggest that phenotypic adaptation of VSMCs to osteo/ chondrocytic-like cells may be involved in the pathogenesis of endogenous smooth muscle Klotho loss. We speculate that Klotho may be a critical gene involved in maintaining smooth muscle cell integrity, and its suppression may be co-ordinated by regulators of osteo/chondrocytic transformation and loss of smooth muscle contractile phenotype in a procalcific milieu.
Previous animal studies have shown that Klotho overexpression imparts longevity 31 and can exert renoprotective effects following ischemia-reperfusion injury, 7 angiotensin II-induced renal failure 32 and glomerulonephritis. 33 Emerging evidence now suggests that Klotho may exert direct cardiovasculoprotective effects; studies using the Otsuka Long-Evans Tokushima Fatty rat that demonstrates multiple atherogenic risk factors have shown that Klotho gene and protein delivery protects against endothelial dysfunction. 6 Several studies have shown that Klotho may protect against vascular damage through the regulation of nitric oxide release. 6, 34 Furthermore, Klotho can confer resistance against oxidative stress involved in the patho- Figure 3 (Continued) . Klotho deficiency accelerates the development of calcification, promotes osteo/chondrocytic transformation and loss of smooth muscle phenotype in HA-SMCs exposed to calcifying stress, in vitro. A, Qualitative assessment of calcification by Alizarin red staining and quantitative assessment of calcification by using the Aresenazo III method in HA-SMCs cultured in calcification medium (CM) for 21 days, revealed calcium deposition. HA-SMCs transfected with klotho siRNA developed a significantly accelerated calcification with marble red staining when compared to the empty vector and nontransfected treatment groups. B, Western blots confirmed reduced Klotho, FGFR-1, and FGFR-3 expression in the empty vector and nontransfected groups treated with CM compared with the control group. However, Klotho, FGFR-1, and FGFR-3 expression was further suppressed in the Klotho siRNA group under calcification medium treatment. C, Western blot analysis of cellular phenotype master regulator showed increased Runx2 protein expression in the nontransfected and empty vector groups following treatment with CM. After further suppression of Klotho protein expression with Klotho siRNA together with CM treatment, even higher Runx2 protein levels were detected in comparison with the CM treatment groups. Myocardin and serum response factor (SRF) protein levels declined opposite to increasing Runx2 protein expression levels, indicating phenotypic transformation of HA-SMCs. This process intensified after suppressing Klotho synthesis with its siRNA construct. D, Alkaline phosphatase measured in the supernatant of the treatment groups showed increased activity under CM treatment, with a further significant raise in activity after knocking down the Klotho protein with its siRNA construct, mirroring Runx2 protein changes. E, HA-SMCs were cultured in CM for 48 hours following Klotho knockdown by Klotho siRNA transfection. Western blot analysis confirmed reduced Klotho in the nontransfected and empty vector groups under CM exposure. Further reduction of Klotho was observed in the Klotho siRNA group. These results were mirrored by calponin, whereas smoothelin and ␣-SMA expression was already significantly decreased after calcification stress alone. This made it difficult to see further reduction after additional Klotho siRNA knockdown. Runx2 expression was increased in the empty vector and nontransfected groups and further increased in the Klotho siRNA group. CM: 2.7 mmol/L CaCl 2 , 2 mmol/L ␤-glycerophosphate. Empty vectorϭlipofectamine alone; nϭ3. One-way ANOVA was used to compare a target protein among treatment groups. probability values from one-way ANOVA are Ͻ0.001 in A through E. Bonferonni post hoc analysis was then performed, and the probability values are provided in the figure. FGFR indicates fibroblast growth factor receptor; siRNA, small interfering RNA; SMA, smooth muscle actin; HA-SMC, human aortic smooth muscle cells.
genesis of various vascular diseases. 4 Klotho has also been shown to suppress retinoid-inducible gene 1-mediated inflammation involved in its antiaging effects. 35 Of note, Hu et al 7 has shown that circulating Klotho can suppress vascular calcification through inhibition of Na ϩ -dependent uptake of phosphate. Our study demonstrates for the first time that local vascular-derived Klotho deficiency in HA-SMCs develops severe calcification when grown un-der procalcific stress conditions. This supports the notion that Klotho deficiency renders arteries vulnerable to dysfunction and that this protein may function as a critical endogenous inhibitor of calcification. We speculate that it may function through the stabilization of VSMC contractile phenotype. Furthermore, our results uncover a new mechanism by which Klotho may exert antiaging and cardiovasculoprotective effects in the arterial system, since osteo/chondrocytic transformation and calcific-hardening of vasculature is characteristic of aged blood vessels. 36, 37 Rising FGF-23 levels in CKD have been associated with a variety of cardiovascular pathologies, including hand artery calcification,. 11 atherosclerosis, 12 and left ventricular hypertrophy. 13 Gutierrez et al 38 showed that rising FGF-23 levels were independently associated with mortality among patients beginning hemodialysis. The recent Heart and Soul study demonstrated that FGF-23 is also independently associated with mortality and cardiovascular disease events in patients without CKD. 14 On the contrary, there is a body of evidence that supports a HA-SMCs were then exposed to high calcium and phosphate (CM). Our results showed that pretreatment with calcitriol could restore Klotho expression most significantly at 50 nmol/L and at the much higher doses of 500 and 1000nmol/L with calcidiol. Calcitriol restored FGFR-1 expression most significantly at 50 nmol/L with no significant effects with calcidiol at these conditions, FGFR-3 expression was restored only by calcitriol at 50nmol/L. B, HA-SMCs treated with calcification medium, FGF-23 at 5 ng/mL or calcitriol at 50 nmol/L for 24 hours independently stimulated cell proliferation. Cell-proliferating effects of FGF-23 and calcitriol were mitigated by concomitant CM stress. However, addition of FGF-23 in the presence CM in HA-SMCs pretreated with calcitriol for 24 hours in combination reversed the inhibitory effect of CM and stimulated proliferation of HA-SMCs. These effects were mitigated by Klotho siRNA. Cells were cultured in 2% charcoal-stripped serum in DMEM. C, HA-SMCs grown in CM for 5 days in 15% charcoal-stripped serum developed significant calcification as assessed by Alizarin red staining and the arsenazo III method. Calcitriol at 50 nmol/L or FGF-23 at 5 ng/mL pretreatment for 24 hours followed by combined treatment with CM did not significantly stimulate or inhibit the development of calcification. However, pretreatment with calcitriol and FGF-23 followed by combined treatment with CM significantly inhibited the development of CM treatment-mediated calcification. These effects were mitigated by Klotho siRNA. Lipofectamine: empty vector, lipofectamine alone. CM: 2 mmol/L ␤-glycerolphosphate and 2.7 mmol/L CaCl 2 ; nϭ6. Oneway ANOVA was used to compare a target protein among treatment groups within a time point. Probability values from 1-way ANOVA are Ͻ0.001 in A through C. Bonferonni post hoc analysis was then performed, and the probability values are provided in the figure. FGFR indicates fibroblast growth factor receptor; siRNA, small interfering RNA; HA-SMC, human aortic smooth muscle cells; FGF-23, fibroblast growth factor 23; CM, calcification medium.
cardiovasculoprotective role for FGF-23: FGF-23 knockout mice present with extensive vascular and soft-tissue calcification, together with severe hyperphosphatemia beginning in early life. 39, 40 Because pathological processes underlying VC resemble bone mineralization, later studies have shown that FGF-23 is able to directly decrease the mineralization of osteoblasts and calvarial cells in vitro. 41, 42 Furthermore, inactivating mutations of FGF-23 in human diseases such as familial tumoral calcinosis manifest with severe ectopic calcification. 15 Because Klotho/FGFR-1 complex forms a specific receptor for FGF-23 signaling in kidney, we hypothesized that VSMCs and the arteries may also be a target for FGF-23 function. In addition, we speculated that vascular Klotho deficiency may mediate FGF-23 resistance, providing an explanation for discrepant findings discussed above. 1, 43 We showed that Klotho colocalizes and physically associates with FGFR-1 and FGFR-3 with suppression and physical dissociation under procalcific stress. FGF-23 upregulates p-ERK and p-AKT, induces proliferation and inhibits HA-SMC-mediated extracellular, calcifying matrix deposition, in vitro. However, these effects were abolished following Klotho knockdown providing first evidence of Klotho-dependent function of FGF-23 in VSMCs. Our results therefore suggest that rising FGF-23 levels in CKD, correlated with increased cardiovascular mortality, are in part a consequence of vascular resistance to FGF-23 because of uremia-mediated VSMC Klotho deficiency. Rising serum FGF-23 levels may themselves be a positive-feedback response as a result of end-organ resistance. This observation is supported by recent studies that have also implicated reduced parathyroid cell Klotho levels as the cause of FGF-23 resistance in uremic CKD rats. 16, 17 Furthermore, our study has shown that deficiency of local vascular Klotho occurs together with declining circulating levels in patients with CKD. 7 Further studies are needed to investigate the interplay between local vascular and circulating Klotho systems.
Large observational clinical studies in patients with CKD have demonstrated that VDR activators impart cardiovascular survival benefits. 44, 45 However, the mechanisms are not well understood. A recent animal study has shown that, at therapeutic dosages sufficient to correct secondary hyperparathyroidism, VDR activator treatment protected the vasculature from calcifying, but higher doses stimulated aortic calcification. 46 The latter was probably caused by indirect, endocrine VDR activator effects resulting in hyperphosphatemia and hypercalcemia, suppressors of vascular Klotho expression. Therapeutic dosages of VDR activator were also found to reduce VSMC phenotype transformation in the aorta. Interestingly, animal studies have shown that administration of calcitriol also increases FGF-23 levels and represents a possible intended protective effect against hyperphosphatemic conditions and also of arteries against raised local calcium and phosphate. 47 In our study, we provide evidence that VDR activation can restore Klotho levels in procalcific environments. This effect appeared to plateau at midrange doses of VDR activator treatment, in vitro. Our results also show that inactive calcidiol can restore Klotho expression, suggesting that the VSMC 1␣-hydroxylase (CYP27B1) enzyme 48 is involved in mediating supportive autocrine/paracrine effects in the regulation of Klotho. Furthermore, we show for the first time that restoration of Klotho with VDR activator renders VSMCs again FGF-23 responsive, with proliferation and calcification inhibitory effects. These results demonstrate that both the endocrine and autocrine/ paracrine vitamin D systems are involved in regulating Figure 6 . Human arteries from patients with CKD retain their ability to restore Klotho and FGFR-1 following treatment with the vitamin D receptor activator calcitriol or paricalcitol in organ culture. Organ culture of human arteries from healthy individuals and patients with CKD treated with calcitriol (100 nmol) or paricalcitol (300 nmol) for 24 hours, Klotho mRNA expression was increased in vehicle-treated artery from patients with CKD in comparison with healthy individuals, whereas mRNA expression of FGFR-1 or FGFR-3 remained suppressed. Both calcitriol and paricalcitol significantly upregulated Klotho and restored FGFR-1 mRNA in arteries from patients with CKD. FGFR-3 mRNA levels remained suppressed despite treatment with calcitriol or paricalcitol. In contrast, no significant effect was observed in arteries from healthy individuals, a vitamin D replete environment without vascular stress, after calcitriol or paricalcitol. Arteries from healthy individuals, nϭ5; arteries from patients with CKD, nϭ15. CM: 2 mmol/L ␤-glycerolphosphate and 2.7 mmol/L CaCl 2 . One-way ANOVA followed by Bonferonni post hoc analysis was used for statistical comparison. FGFR indicates fibroblast growth factor receptor; CKD, chronic kidney disease; CM, calcification medium. local vascular Klotho. VDR activator alone had no modulating effect on VSMC calcification in our in vitro model. This would support the concept of a complex interplay on a local tissue level between the vitamin D system-Klotho-FGF-23 beyond mineral homeostasis, as proposed by Haussler et al 49 on an endocrine level for this system, resulting in protection of the vasculature. Human arterial organ cultures confirmed that arteries from CKD patients retained their ability to restore Klotho and FGFR-1 following VDR activator treatment. We therefore propose that use of VDR activator as a therapeutic strategy in CKD for the restoration of vascular Klotho deficiency and the vascular FGF-23 response.
In conclusion, we report for the first time endogenous Klotho expression in human arteries, in vivo, and in HA-SMCs, in vitro. We provide evidence that CKD is a state of vascular Klotho deficiency, a likely explanation for accelerated vascular aging with calcification experienced by these patients. We have also shown that high levels of FGF-23 in CKD cannot be vasculoprotective because Klotho/FGFR deficiency mediates resistance. And we confirm that VDR activator therapy mediates vascular protection by increasing vascular Klotho expression and rendering vascular cells FGF-23 responsive. Our study furthers our understanding of the role of vascular Klotho in accelerated vascular disease and the interplay it mediates between FGF-23 and vascular cells.
